Abstracts tagged "Inflammation"

Abstract Number: 887 • 2019 ACR/ARP Annual Meeting
Critical Role of the Cholinergic System Involvement in Osteoarthritis
Alice Courties¹, Ariane Do ¹, Sarah Leite ², Audrey Pigenet ², Morgane Belle ³, Geoffroy Nourissat ⁴, Alain Sautet ⁵, Alain Chedotal ³, Uwe Maskos ⁶, Francis Berenbaum ⁷ and Jérémie Sellam ¹, ¹Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ²Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ³Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France, Paris, France, ⁴Chirurgie orthopédique, Clinique Maussins, Groupe Ramsay générale de santé, 67 rue de Romainville, 75019, Paris, Paris, France, ⁵Chirurgie orthopédique, AP-HP Hôpital Saint-Antoine, Paris, Paris, France, ⁶Unité de neurobiologie intégrative des systèmes cholinergiques, CNRS UMR 3571, Institut Pasteur, Paris, Paris, France, ⁷Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France
Background/Purpose: The efferent vagus nerve can regulate inflammation via its principal neurotransmitter acetylcholine (ACh), a concept referred as the 'cholinergic anti-inflammatory pathway'. ACh interacts with members of…
Abstract Number: 979 • 2019 ACR/ARP Annual Meeting
Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice
Bhanupriya Madarampalli¹, Paul Panipinto ¹, Erica Chow ¹, Kendahl Sugai ¹, Fanqi Shi ¹ and Erika Noss ¹, ¹University of Washington, Seattle, WA
Background/Purpose: The interplay between infiltrating immune cells and activated joint stromal cells drives inflammation, cartilage destruction, and bone erosion in rheumatoid arthritis (RA). Among joint…
Abstract Number: 1228 • 2019 ACR/ARP Annual Meeting
Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout
Vitaly Kliminski ¹ and Yair Molad², ¹Laboratory of Inflammation Research, Felsenstein Medical Research Center, Tel Aviv University, Petach Tikva, Israel, ²Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel
Background/Purpose: Myeloid cells membrane-bound TREM-1 (mTREM-1) amplifies toll like receptor (TLR)-4-mediated myeloid cells activation, accompanied by release of soluble TREM-1 (sTREM-1) that acts as a…
Abstract Number: 1521 • 2019 ACR/ARP Annual Meeting
Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Walter P. Maksymowych¹, Gaia Gallo ², Rebecca Bolce ³, Fangyi Zhao ², Vladimir Geneus ³, Mikkel Østergaard ⁴, Kurisu Tada ⁵, Atul Deodhar ⁶ and Lianne Gensler ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵Juntendo University School of Medicine, Tokyo, Japan, ⁶Oregon Health & Science University, Portland, OR, ⁷University San Francisco California, San Francisco, CA
Background/Purpose: IL-17 plays an important role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Elevated CRP levels in serum predict response to TNF inhibitors (TNFi).1-4…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 1003 • 2018 ACR/ARHP Annual Meeting
Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions
Sladjana Skopelja-Gardner¹, Xizhang Sun², Joyce Tai³, Lucrezia Colonna³, Lena Tanaka⁴ and Keith B. Elkon⁵, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Medicine/Rheumatology, University of Washington, Seattle, WA, ⁵University of Washington, Seattle, WA
Background/Purpose: Two-thirds of systemic lupus erythematosus (SLE) patients are sensitive to sunlight and artificial light. Ultraviolet (UV) B light induces sterile inflammation in the skin…
Abstract Number: 2101 • 2018 ACR/ARHP Annual Meeting
UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming
Masaoki Kawasumi¹, Daiki Rokunohe¹, Xizhang Sun², Lena Tanaka², Sladjana Skopelja-Gardner³, Edward Chiou², Anne Davidson⁴, Sandra L. Wolin⁵ and Keith B. Elkon², ¹Medicine/Dermatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Feinstein Institute for Medical Research, Manhasset, NY, ⁵National Cancer Institute, Frederick, MD
Background/Purpose: Photosensitivity is a major symptom of lupus, and excessive sunlight can cause skin rashes and flares of disease activity in systemic lupus erythematosus (SLE).…
Abstract Number: 1012 • 2018 ACR/ARHP Annual Meeting
Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages
Rajan Bhandari¹, Michael Ball², Saemi Han², Kathleen Aren³, Mary A. Carns³, Monique Hinchcliff⁴, Michael L. Whitfield⁵, Karen Liby⁶ and Patricia A. Pioli⁷, ¹Geisel School of Medicine at Dartmouth, lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Rheumatology, Northwestern University, Chicago, IL, ⁵Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁶Michigan State University, East Lansing, MI, ⁷Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology that is characterized by vasculopathy, fibrosis, and inflammation. Our work and that of…
Abstract Number: 2211 • 2018 ACR/ARHP Annual Meeting
Technetium Tc 99m Tilmanocept: A Targeted Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial Macrophage Activity in Rheumatoid Arthritis
Arash Kardan¹, Allison Kissling², Bonnie Abbruzzese², Ahmad Ismail², Rachael Hershey², Carley Hartings², David Ralph², Izabela Gierach², Michael Blue², Hannah Bailey², Christopher Gablemann², Katherine Repp² and Frederick Cope², ¹Charles F. Kettering Memorial Hospital and Wright State University Boonshoft School of Medicine, Dayton, OH, ²Navidea Biopharmaceuticals, Inc., Dublin, OH
Background/Purpose: Activated macrophages are a critical component of the inflammatory etiology of RA. It is well established that these macrophages perpetuate joint inflammation and destruction…
Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner¹, Anil K. Singh¹ and Salahuddin Ahmed^1,2, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…
Abstract Number: 2245 • 2018 ACR/ARHP Annual Meeting
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Anthony M. Reginato¹, Changqi Sun², Elsaid A. Khaled³, Tannin A. Schmidt⁴, Olin D. Liang⁵ and Gregory D Jay⁶, ¹Division of Rheumatology, Rhode Island Hospital, Providence, RI, ²Division of Rheumatology, Rhode Island Hospital, Providence, MA, ³Department of Biomedical and Phramaceutical Science, Chapman University School of Pharmacy, Irvine, CA, ⁴Biomedical Engineering, University of Connecticut Health Center, Framington, CT, ⁵Division of Hematology/Oncology, Rhode Island Hospital, Providence, RI, ⁶Department of Emergency Medicine, Rhode Island Hospital, Providence, RI
Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including…
Abstract Number: 1077 • 2018 ACR/ARHP Annual Meeting
Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis
Simone Perniola¹, Liliana Dinoia¹, Nunzia Lacarpia¹, Dorotea Natuzzi¹, Rita Bizzoca¹ and Florenzo Iannone², ¹Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ²D.E.T.O., Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy
Background/Purpose: Inflammation is part of the complex biological response of body tissues to harmful stimuli, involving immune cells, blood vessels, and molecular mediators. At the…
Abstract Number: 2264 • 2018 ACR/ARHP Annual Meeting
Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases
Anna Postolova¹ and Mark C. Genovese², ¹Department of Medicine, Stanford University Medical Center, Palo Alto, CA, ²Department of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Granulomatous Mastitis is a rare, inflammatory disease of the breast. Presenting symptoms in the breast can be unilateral or bilateral pain, masses, skin induration,…
Abstract Number: 1170 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Associations between Systemic Inflammatory Cytokines and Osteoarthritis Knee Pain
Anthony V. Perruccio¹, J. Denise Power¹, Mayilee Canizares¹, Elizabeth M. Badley^1,2, Mohit Kapoor¹, Rajiv Gandhi¹ and Y. Raja Rampersaud¹, ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Significant challenges remain in mitigating OA pain and despite growing evidence of sex differences, including in pain and in response to NSAIDs, sex has…
Abstract Number: 2508 • 2018 ACR/ARHP Annual Meeting
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
David Chernoff¹, Yaakov Levine¹, Charles Peterfy² and Mark C. Genovese³, ¹SetPoint Medical, Inc., Valencia, CA, ²Spire Sciences LLC, Boca Raton, FL, ³Department of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Bioelectronic therapy (BET), such as electrical neurostimulation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].